fig1

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Figure 1. (A). Anterior wall myocardial blood flow in sham (N = 11), at the time of acute myocardial infarction (MI, N = 7), MI at 3 weeks (N = 4), and MI at 3 weeks with 3DFC (N = 4). Note that the 3-dimensional fibroblast construct (3DFC) improved blood flow in the infarcted wall. Values are mean ± SE; *P < 0.05 versus baseline and MI (3w) + 3DFC[7]. Cell Transplantation 2009;3:283-296. (B). Vessel density defined by Factor VIII staining. Note the increase in vessel density in the area with the 3-dimensional fibroblast construct (3DFC) compared to the untreated myocardial infarction (MI). MI (N = 9), MI + 3DFC (N = 8). Values are mean ± SE. *P < 0.05 versus MI[7].

Vessel Plus
ISSN 2574-1209 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/